Thompson Siegel & Walmsley LLC raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 10.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 565,337 shares of the company's stock after purchasing an additional 51,705 shares during the quarter. Thompson Siegel & Walmsley LLC owned approximately 0.08% of Roivant Sciences worth $6,688,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the stock. TOMS Capital Investment Management LP bought a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $46,333,000. FMR LLC increased its position in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after buying an additional 2,593,910 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after buying an additional 1,460,205 shares during the last quarter. State Street Corp lifted its position in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after buying an additional 1,118,561 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Roivant Sciences by 49.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company's stock worth $26,625,000 after acquiring an additional 762,953 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.
Roivant Sciences Price Performance
NASDAQ ROIV traded down $0.14 on Tuesday, reaching $10.71. The stock had a trading volume of 3,638,684 shares, compared to its average volume of 5,497,675. The company has a market cap of $7.64 billion, a P/E ratio of -71.40 and a beta of 1.26. The firm has a fifty day moving average of $10.80 and a two-hundred day moving average of $11.49. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $18.08.
Get Our Latest Report on Roivant Sciences
Insiders Place Their Bets
In other news, COO Eric Venker sold 218,041 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,345,374.98. This represents a 19.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 2,388,170 shares of company stock worth $27,612,299 in the last quarter. Corporate insiders own 7.90% of the company's stock.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
